For informational purposes only — not investment advice

← Back to signals

TECH

SHORT

BIO-TECHNE CORP

Research: Finviz ↗·Perplexity ↗

🗄 Viewing archived Q2 2026 data — frozen, no longer refreshed.

Funds
4
Score
3.86
vs SPY
+3.9%
Stock return (since Q-end)
+3.3%
SPY return (since Q-end)
-0.7%
Current price
$72.79
Days to cover (short int.)
2.1d↓-53.6%
as of 2026-09-30 · shares short vs 2026-06-30

News Summary

Neutral

Bio-Techne announced a $11.3 billion acquisition by Merck KGaA at $73/share (June 25, 2026), which dominates the investment narrative going forward. Operationally, the company delivered mixed results with Q3 earnings miss followed by Q4 beat, flat full-year revenue growth, and persistent cell-therapy headwinds offset by strong growth in spatial biology (COMET >65% growth) and proteomics platforms, with management guiding to flat Q4 organic growth but mid-single-digit growth expected in FY2027 as biotech spending normalizes.

Red flags

  • •Q3 FY2026 earnings missed consensus by $0.01 EPS and $4.7M revenue (1.49% shortfall)
  • •Full-year FY2026 revenue flat year-over-year at $1.2 billion
  • •11 analysts downwardly revised FY2027 earnings estimates; conservative guidance of $0.46-$0.60 EPS per quarter
  • •Persistent near-term headwinds in emerging biotech spending and cell-therapy timing issues
  • •Pending acquisition creates execution risk and uncertainty until close

Funds Reducing / Exiting (4)

FundManagerShares Held∆ SharesPosition Value% of FundQoQStatus
Maverick CapitalLee Ainslie1.5M-3,203,927$108M2.9%-68%Existing
Durable Capital PartnersHenry Ellenbogen502K-3,955,968$35M2.4%-89%Existing
Glenview CapitalLarry Robbins58K-128,015$4M0.3%-69%Existing
Point72Steve Cohen0−295K—<0.1%-100%EXITED

Shares Held reflects quarter-end positions for partial reductions. Funds that fully exited show 0 shares held. ∆ Shares is the change from the prior quarter. % of Fund is the prior-quarter position size — how much of the book was sold down.

Signal History

QuarterDirectionFundsScorevs SPY
Q2 2026SHORT43.86+3.9%
Q1 2026LONG33.85+19.1%

Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.

Beneficial Ownership (13D/13G)

FilerFormShares% of ClassFiledSrc
FMR LLCSC 13G/A1.1M0.7%2026-11-05↗
FMR LLCSC 13G/A12.8M8.1%2026-08-06↗
FMR LLCSC 13G7.9M5.0%2026-05-06↗
Vanguard Capital ManagementSC 13G11.6M7.4%2026-04-29↗

SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.